William L. Moore
All posts from William L. Moore
William L. Moore in Insider trading,

Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers

Pharmaceutical giants Bristol-Myers Squibb Co  and Merck & Co., Inc.  both release their second quarter earnings reports this week.

According to BMO Capital, investors should be buying Merck and selling Bristol-Myers ahead of earnings.

Despite Merck being on the verge of five years of delivering solid growth, BMO analyst Alex Arfaei believes that some of the company’s assets are still under-appreciated.

Cancer immunotherapy drug Keytruda is seeing a significant increase in use, from 20 percent reported use, up from around 3 percent use in April, and could see $12 billion in sales by 2026. BMO is forecasting Keytruda to deliver $3.7 billion in sales in 2017.

Read more